Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.56 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45541 | 0.91 | SYK (0.56) | SYKFOLH1CTSLCTSSCTSK | |
| SCHEMBL23538215 | 0.91 | SYK (0.56) | SYKFOLH1CTSLCTSSCTSK | |
| SCHEMBL5970914 | 0.91 | SYK (0.56) | SYKFOLH1CTSLCTSSCTSK | |
| SCHEMBL10389689 | 0.90 | SIRT2 (0.62) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL30649083 | 0.88 | SYK (0.54) | SIRT2SIRT1SIRT3SYKCTSL | |
| SCHEMBL10166824 | 0.88 | SYK (0.54) | SIRT2SIRT1SIRT3SYKCTSL | |
| SCHEMBL26896562 | 0.88 | CTSL (0.60) | SIRT2SIRT1SIRT3SYKCTSL | |
| SCHEMBL20450593 | 0.88 | FOLH1 (0.60) | SIRT2SIRT1SIRT3FOLH1HTT | |
| SCHEMBL20450594 | 0.88 | FOLH1 (0.60) | SIRT2SIRT1SIRT3FOLH1HTT | |
| SCHEMBL31301793 | 0.87 | SYK (0.53) | SIRT2SIRT1SIRT3SYKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040266818-A1 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | SIRT2 156/4885SIRT1 116/4885SIRT3 222/4885 |
| US-20040266818-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | SIRT2 156/4885SIRT1 116/4885SIRT3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.